Severe abdominal pain was one of the first signs of pancreatic cancer for Paula Rowland. She ignored it for months. After ...

A team of researchers has developed a "gut-on-chip" (a miniature model of the human intestine on a chip-sized device) capable ...

A new University of Kentucky Markey Cancer Center study provides important insights for future clinical trials in treating ...

Researchers from The Institute of Cancer Research, London, and Barts Cancer Institute have discovered how the extracellular matrix (ECM) surround ...

The failure in adjuvant melanoma could cause BMS and Opdualag to miss out on a market opportunity that is nearly twice as large as its current approved indication, according to analysts.

The combination therapy failed to beat out the company’s other cancer therapy, Opdivo, in patients living with melanomas.

Upon Opdualag’s approval in 2022 as a first-in-class cancer immunotherapy, Bristol Myers Squibb was anxious to explore its potential in a variety of indications. | Bristol Myers Squibb is striking out ...

Cancer breakthrough as scientists find way to spot aggressive tumours before they spread - The discovery could pave the way ...